磁共振灌注成像在乳腺癌新辅助化疗疗效评价中的价值  

作　　者：孙晨 

机构地区：[1]浙江省金华市妇幼保健院,321000

出　　处：《浙江临床医学》2024年第12期1859-1860,1865,共3页Zhejiang Clinical Medical Journal

基　　金：金华市重点科技计划项目(2021-3-134)。

摘　　要：目的探究磁共振灌注成像(PMRI)在乳腺癌新辅助化疗(NAC)疗效评价中的价值。方法回顾性分析2022年1月至2023年11月进展期乳腺癌患者31例,根据RECIST疗效评估标准,将患者分为治疗有效组(n=15)及治疗无效组(n=16),比较两组患者新辅助化疗治疗前、第1疗程结束后、术前末次治疗结束后的药代动力学定量(Ktrans、Kep及Ve)及肿瘤长径。结果两组患者第1疗程结束后、术前末次治疗结束后Ktrans、Kep及Ve定量参数比较,差异有统计学意义(P<0.05)。结论磁共振灌注成像PMRI定量参数能预判乳腺癌新辅助化疗疗效,为进一步治疗提供参考。Objective To explore the value of perfusion magnetic resonance imaging(PMRI)in evaluating the response to neoadjuvant chemotherapy(NAC)in breast cancer.Methods A total of 31 patients with advanced breast cancer admitted to our hospital from January 2022 to November 2023 were retrospectively analyzed.According to the RECIST efficacy evaluation criteria,the patients were divided into the effective group(n=15)and the ineffective group(n=16).The pharmacokinetic parameters(Ktrans,Kep,Ve)and tumor diameter were compared between the two groups before neoadjuvant chemotherapy,after the first course of neoadjuvant chemotherapy,and after the last treatment before surgery.Results There were significant differences in the quantitative parameters of Ktrans,Kep and Ve between the two groups after the first course of treatment and after the last preoperative treatment(P<0.05).Conclusion PMRI quantitative parameters can predict the response to neoadjuvant chemotherapy in breast cancer,and provide reference for further treatment.

关 键 词：乳腺癌 磁共振 新辅助化疗 PMRI 定量参数 

分 类 号：R737.9[医药卫生—肿瘤] R445.2[医药卫生—临床医学]